ONCOCYTE CORP (OCX) Stock Price, Forecast & Analysis
USA - NASDAQ:OCX - US68235C2061 - Common Stock
OCX Key Statistics, Chart & Performance
The current stock price of OCX is 3.2 USD. In the past month the price increased by 14.29%. In the past year, price increased by 13.07%.
OCX Latest News, Press Relases and Analysis
OCX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About OCX
Company Profile
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 46 full-time employees. The company went IPO on 2015-12-30. The firm is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.
Company Info
ONCOCYTE CORP
15 Cushing
Irvine CALIFORNIA 92618 US
CEO: Ronald Andrews
Employees: 48
Phone: 19494097600
ONCOCYTE CORP / OCX FAQ
Can you describe the business of ONCOCYTE CORP?
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 46 full-time employees. The company went IPO on 2015-12-30. The firm is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.
Can you provide the latest stock price for ONCOCYTE CORP?
The current stock price of OCX is 3.2 USD. The price increased by 17.22% in the last trading session.
What is the dividend status of ONCOCYTE CORP?
OCX does not pay a dividend.
How is the ChartMill rating for ONCOCYTE CORP?
OCX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about ONCOCYTE CORP (OCX) stock?
8 analysts have analysed OCX and the average price target is 5.53 USD. This implies a price increase of 72.66% is expected in the next year compared to the current price of 3.2.
What is the expected growth for OCX stock?
The Revenue of ONCOCYTE CORP (OCX) is expected to grow by 508.91% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is ONCOCYTE CORP worth?
ONCOCYTE CORP (OCX) has a market capitalization of 91.52M USD. This makes OCX a Micro Cap stock.
OCX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to OCX. When comparing the yearly performance of all stocks, OCX turns out to be only a medium performer in the overall market: it outperformed 50.23% of all stocks.
OCX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OCX. OCX has a bad profitability rating. Also its financial health evaluation is rather negative.
OCX Financial Highlights
Over the last trailing twelve months OCX reported a non-GAAP Earnings per Share(EPS) of -3.53. The EPS increased by 31.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -96.52% | ||
| ROE | -570.19% | ||
| Debt/Equity | 0.05 |
OCX Forecast & Estimates
8 analysts have analysed OCX and the average price target is 5.53 USD. This implies a price increase of 72.66% is expected in the next year compared to the current price of 3.2.
For the next year, analysts expect an EPS growth of 78.19% and a revenue growth 508.91% for OCX